Beckhaus Andrea A, Riutort Maria C, Castro-Rodriguez Jose A
Department of Pediatrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Pediatr Pulmonol. 2014 Apr;49(4):326-34. doi: 10.1002/ppul.22846. Epub 2013 Aug 8.
To compare the effects of inhaled corticosteroids (ICS) against systemic corticosteroids (SC) in children consulting in emergency department (ED) or equivalent for asthma exacerbation.
Electronic search in MEDLINE, CENTRAL, CINAHL, and LILACS databases and other sources. Study selection criteria: children 2-18 years of age, consulting in ED or equivalent for asthma exacerbation, comparison between ICS and SC, randomized controlled trials.
hospital admission rate, unscheduled visits for asthma symptoms, need of additional course of SC.
improvement of lung function, length of stay in ED, clinical scores, and adverse effects.
Eight studies met inclusion criteria (N = 797), published between 1995 and 2006. All used prednisolone as SC and budesonide, fluticasone, dexamethasone, and flunisolide were administered as ICS. No significant difference between ICS versus SC was found in terms of hospital admission (RR: 1.02; 95% CI: 0.41-2.57), unscheduled visits for asthma symptoms (RR: 9.55; 95% CI: 0.53-170.52) nor for need of additional course of SC (RR: 1.45; 95% CI: 0.28-7.62). The change in % of predicted FEV1 at fourth hour was significantly higher for SC group, but there was no significant difference between both groups after this time. There was insufficient data to perform meta-analysis of length of stay during first consult in ED and of symptom scores. Vomiting was similar among both groups.
There is no evidence of a difference between ICS and SC in terms of hospital admission rates, unscheduled visits for asthma symptoms and need of additional course of SC in children consulting for asthma exacerbations.
比较吸入性糖皮质激素(ICS)与全身性糖皮质激素(SC)对因哮喘急性加重而到急诊科或同等科室就诊的儿童的治疗效果。
对MEDLINE、CENTRAL、CINAHL和LILACS数据库及其他来源进行电子检索。研究选择标准:年龄在2至18岁之间、因哮喘急性加重到急诊科或同等科室就诊、ICS与SC的比较、随机对照试验。
住院率、因哮喘症状进行的非计划就诊、额外使用SC疗程的需求。
肺功能改善情况、在急诊科的住院时间、临床评分及不良反应。
八项研究符合纳入标准(N = 797),发表于1995年至2006年之间。所有研究均使用泼尼松龙作为SC,布地奈德、氟替卡松、地塞米松和氟尼缩松作为ICS给药。在住院率(RR:1.02;95%CI:0.41 - 2.57)、因哮喘症状进行的非计划就诊(RR:9.55;95%CI:0.53 - 170.52)或额外使用SC疗程的需求(RR:1.45;95%CI:0.28 - 7.62)方面,未发现ICS与SC之间存在显著差异。SC组在第4小时预测FEV1百分比的变化显著更高,但此后两组之间无显著差异。没有足够的数据对首次在急诊科就诊时的住院时间和症状评分进行荟萃分析。两组呕吐情况相似。
对于因哮喘急性加重而就诊的儿童,在住院率、因哮喘症状进行的非计划就诊以及额外使用SC疗程的需求方面,没有证据表明ICS与SC之间存在差异。